Is<sup>18</sup>F-FDG Metabolic Tumor Volume in Lymphoma Really Happening?
Sally F. Barrington, Anne‐Ségolène Cottereau, Josée M. Zijlstra
Abstract
Tumor burden influences prognosis in lymphoma, with unidimensional bulk used for risk assessment and decisions about radiotherapy consolidation ([1][1]). Total metabolic tumor volume (TMTV) using 18F-FDG PET emerged 10 y ago as a promising biomarker ([2][2]) that was superior to bulk ([3][3]).
Topics & Concepts
LymphomaRadiation therapyBiomarkerMedicineHodgkin lymphomaNuclear medicineOncologyConsolidation (business)Internal medicineChemistryBusinessAccountingBiochemistryLymphoma Diagnosis and TreatmentMedical Imaging Techniques and ApplicationsLung Cancer Treatments and Mutations